Pancreatic Cancer Research

ResearcherSichuan UniversityNo recent work listed

Weiting Liao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0667-2046; OpenAlex author ID A5071098126. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper

Papers 3

  1. Circulating gamma-glutamyl transpeptidase and risk of pancreatic cancer: A prospective cohort study in the UK Biobank. Co-author DOI 10.1002/cam4.5556↗
  2. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial. Co-author DOI 10.1080/14737167.2020.1677155↗
  3. Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial. First author DOI 10.2147/cmar.s172704↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qiu Li · 1 shared paper, 2023 · strength 0.22
  2. Kexun Zhou · 2 shared papers, 2018–2020 · strength 0.18
  3. Jiaxing Huang · 2 shared papers, 2018–2020 · strength 0.18
  4. Qiu Li · 2 shared papers, 2018–2020 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.